CeriBell, Inc. (NASDAQ:CBLL) Receives Consensus Rating of “Moderate Buy” from Analysts

CeriBell, Inc. (NASDAQ:CBLL) has earned a consensus recommendation of “Moderate Buy” from the seven ratings firms that are covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, four have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $24.40.

Several brokerages recently commented on CBLL. Weiss Ratings upgraded CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday. BTIG Research reaffirmed a “buy” rating and issued a $30.00 price objective on shares of CeriBell in a research report on Friday, September 11th. Barclays upgraded shares of CeriBell to a “neutral” rating in a research note on Tuesday, August 18th. Canaccord Genuity Group boosted their target price on shares of CeriBell from $25.00 to $26.00 and gave the stock a “buy” rating in a research report on Tuesday, August 11th. Finally, Raymond James Financial reaffirmed a “strong-buy” rating and set a $29.00 price target on shares of CeriBell in a report on Thursday, September 3rd.

Insider Buying and Selling

In related news, VP David Foehr sold 9,255 shares of the business’s stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $24.25, for a total value of $224,433.75. Following the transaction, the vice president owned 34,144 shares in the company, valued at approximately $827,992. The trade was a 21.33% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Xingjuan Chao sold 39,540 shares of the stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $24.61, for a total value of $973,079.40. Following the completion of the transaction, the chief executive officer directly owned 767,191 shares of the company’s stock, valued at $18,880,570.51. This represents a 4.90% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 413,593 shares of company stock worth $9,085,381 over the last quarter. Company insiders own 17.70% of the company’s stock.

Institutional Investors Weigh In On CeriBell

Hedge funds and other institutional investors have recently bought and sold shares of the business. Squarepoint Ops LLC bought a new stake in shares of CeriBell in the second quarter worth $638,000. Wellington Management Group LLP boosted its stake in CeriBell by 5.5% during the 2nd quarter. Wellington Management Group LLP now owns 87,698 shares of the company’s stock valued at $1,706,000 after acquiring an additional 4,572 shares during the last quarter. Formula Growth Ltd. bought a new position in CeriBell during the 2nd quarter valued at $603,000. Bank of America Corp DE acquired a new position in CeriBell during the 2nd quarter worth $4,619,000. Finally, PDT Partners LLC bought a new stake in shares of CeriBell in the 2nd quarter worth about $1,026,000.

CeriBell Stock Down 0.5%

CeriBell stock traded down $0.13 during trading on Friday, reaching $24.87. 40,847 shares of the company’s stock were exchanged, compared to its average volume of 342,233. The company’s 50-day moving average is $21.51 and its two-hundred day moving average is $19.79. The company has a debt-to-equity ratio of 0.16, a quick ratio of 8.79 and a current ratio of 9.18. CeriBell has a 52-week low of $10.85 and a 52-week high of $25.63. The firm has a market cap of $954.55 million, a price-to-earnings ratio of -14.13 and a beta of 0.95.

CeriBell (NASDAQ:CBLL) last released its quarterly earnings data on Monday, August 10th. The company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.47) by ($0.04). The company had revenue of $28.10 million during the quarter, compared to analysts’ expectations of $27.28 million. CeriBell had a negative net margin of 64.73% and a negative return on equity of 44.85%. On average, analysts predict that CeriBell will post -1.96 earnings per share for the current year.

CeriBell Company Profile

Ceribell, Inc (NASDAQ: CBLL) is a medical technology company focused on improving the detection and management of seizures and other neurological conditions in hospital settings. Its products are designed to make electroencephalography (EEG) more accessible at the point of care, particularly in emergency departments, intensive care units and other settings where conventional EEG testing may be delayed or difficult to obtain.

The company’s primary offering is the Ceribell Rapid Response EEG system, which combines a portable EEG recorder, a simplified electrode headband and software for acquiring and reviewing brain-wave data.